Jade Biosciences Inc.

JBIO | NASDAQ

Price Alert Chart Builder DCF Calculator

$14.06

-$0.18 (-1.26%)

At close: Oct 30, 2026, 4:00 PM ET

$14.00

-$0.06 (-0.43%)

Pre-market: Nov 2, 2026, 7:27 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.26%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

24.8

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #926/1028 (Top 90%)

Full Analysis

Key Statistics

Market Data

Market Cap $894.18M

1D Range

13.83 14.35

52W Range

8.95 26.85

Valuation (TTM)

PE -5.11

PB 2.03

EV/EBITDA -2.77

Valuation (NTM)

Forward PE N/A

Forward PEG -2.04

Price Target $48.40

Cash Flow

FCF Yield -13.8%

SBC Adj. FCF Yield -16.2%

SBC Impact -17.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 76.2% | 7.8%

FCF 3Y | 5Y -25.5% | -28.7%

Returns

ROA -32.5%

ROE -49.1%

ROIC -37.4%

Financial Health

Net Cash

$461.21M

Current Ratio 14.93

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoc...

Sector Healthcare

Industry Biotechnology

Employees 55

IPO Date Jun 30, 2021

Website jadebiosciences.com

Fiscal Year January - December

Full Company Profile

Latest News

2 months ago · globenewswire.com

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Tuesday, September 8 at 3:45 p.m.

3 months ago · seekingalpha.com

Jade Biosciences: Duration Is The Real Product

Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$47.00

Upside

+234.28%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞